Pre-Emptive Kidney Retransplantation from Deceased Donors

A. Franco Esteve, P. Más-Serrano, Fransico Manuel Marco, Eduardo Garin Cascales, Francisco Javier Pérez Contreras
{"title":"Pre-Emptive Kidney Retransplantation from Deceased Donors","authors":"A. Franco Esteve, P. Más-Serrano, Fransico Manuel Marco, Eduardo Garin Cascales, Francisco Javier Pérez Contreras","doi":"10.3390/transplantology5010004","DOIUrl":null,"url":null,"abstract":"There is uncertainty about the best approach to replacement treatment for kidney transplant recipients with chronic terminal graft dysfunction, since a retransplant could be performed before the resumption of dialysis, thus avoiding this treatment and the dilemma of whether or not to suspend immunosuppressive therapy. However, there is limited experience in pre-emptive repeat transplantations, and none from deceased donors. This study aims to assess the results of a pre-emptive retransplantation program with brain-dead deceased donors. We designed a retrospective matched cohort study, including 36 recipients in the pre-dialysis group and 36 controls who were already on dialysis, matched for donor age and transplant date, which could not differ by more than 7 days between pairs. The variables used to standardize the cohorts were donor and recipient age and sex, blood group, duration of the first graft, time on the waitlist to receive the second graft, cold ischemia time, induction and maintenance of immunosuppression, and HLA antibodies (-) prior to retransplantation. The efficacy variables were early graft loss, acute rejection, delay in graft function, renal function at the end of follow-up, survival time, and recipient and graft survival at 24 and 48 months’ follow-up. The pre-dialysis group presented a significantly shorter waitlist time, lower immunization status, and a significantly longer duration of the first graft than the control group. The percentage of recipients who presented early graft loss, delayed renal function, or acute rejection was similar between groups. No significant differences were observed in kidney function or in the survival of the recipient or graft. Retransplantation yields good outcomes in patients with terminal chronic dysfunction, helping to avoid recurrence to dialysis, shortening the time spent on the waitlist, reducing the risk of producing antibodies, and resolving the dilemma of whether or not to stop immunosuppression.","PeriodicalId":503806,"journal":{"name":"Transplantology","volume":"82 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/transplantology5010004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

There is uncertainty about the best approach to replacement treatment for kidney transplant recipients with chronic terminal graft dysfunction, since a retransplant could be performed before the resumption of dialysis, thus avoiding this treatment and the dilemma of whether or not to suspend immunosuppressive therapy. However, there is limited experience in pre-emptive repeat transplantations, and none from deceased donors. This study aims to assess the results of a pre-emptive retransplantation program with brain-dead deceased donors. We designed a retrospective matched cohort study, including 36 recipients in the pre-dialysis group and 36 controls who were already on dialysis, matched for donor age and transplant date, which could not differ by more than 7 days between pairs. The variables used to standardize the cohorts were donor and recipient age and sex, blood group, duration of the first graft, time on the waitlist to receive the second graft, cold ischemia time, induction and maintenance of immunosuppression, and HLA antibodies (-) prior to retransplantation. The efficacy variables were early graft loss, acute rejection, delay in graft function, renal function at the end of follow-up, survival time, and recipient and graft survival at 24 and 48 months’ follow-up. The pre-dialysis group presented a significantly shorter waitlist time, lower immunization status, and a significantly longer duration of the first graft than the control group. The percentage of recipients who presented early graft loss, delayed renal function, or acute rejection was similar between groups. No significant differences were observed in kidney function or in the survival of the recipient or graft. Retransplantation yields good outcomes in patients with terminal chronic dysfunction, helping to avoid recurrence to dialysis, shortening the time spent on the waitlist, reducing the risk of producing antibodies, and resolving the dilemma of whether or not to stop immunosuppression.
从已故捐献者处进行先天性肾脏再移植
对于慢性终末期移植物功能障碍的肾移植受者来说,替代治疗的最佳方法尚不确定,因为可以在恢复透析前进行再次移植,从而避免这种治疗和是否暂停免疫抑制治疗的两难选择。然而,目前在先期重复移植方面的经验非常有限,而且没有来自已故捐献者的经验。本研究旨在评估脑死亡捐献者抢先再移植计划的结果。我们设计了一项回顾性配对队列研究,其中包括 36 名透析前组受者和 36 名已在透析的对照组受者,两组受者的供体年龄和移植日期相匹配,两组之间的差异不得超过 7 天。用于标准化队列的变量包括供体和受体的年龄和性别、血型、第一次移植的持续时间、等待接受第二次移植的时间、冷缺血时间、免疫抑制的诱导和维持以及再次移植前的 HLA 抗体 (-)。疗效变量包括早期移植物丢失、急性排斥反应、移植物功能延迟、随访结束时的肾功能、存活时间以及随访 24 个月和 48 个月时受者和移植物的存活率。与对照组相比,透析前组的等待时间明显较短、免疫状态较差、首次移植时间明显较长。两组出现早期移植物丢失、肾功能延迟或急性排斥反应的受者比例相似。肾功能、受者或移植物的存活率均无明显差异。再移植为终末期慢性功能障碍患者带来了良好的治疗效果,有助于避免再次透析,缩短等待时间,降低产生抗体的风险,并解决是否停止免疫抑制的难题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书